Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/201724
SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
High-grade gliomas (HGG) are the most common primary brain malignancies and account for more than half of all malignant primary brain tumors. The new 2021 WHO classification divides adult HGG into four subtypes: grade 3 oligodendroglioma (1p/19 codeleted, IDH-mutant); grade 3 IDH-mutant astrocytoma; grade 4 IDH-mutant astrocytoma, and grade 4 IDH wild-type glioblastoma (GB). Radiotherapy (RT) and chemotherapy (CTX) are the current standard of care for patients with newly diagnosed HGG. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent high-grade gliomas is not well defined and decision-making is usually based on prior strategies, as well as several clinical and radiological factors. Whereas the prognosis for GB is grim (5-year survival rate of 5-10%) outcomes for the other high-grade gliomas are typically better, depending on the molecular features of the tumor. The presence of neurological deficits and seizures can significantly impact quality of life.
Subject (English)
Citation
Citation
PÉREZ SEGURA, Pedro, et al. SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022). Clinical and Translational Oncology. 2023. Vol. 25, num. 9, pags. 2634-2646. ISSN 1699-3055. [consulted: 19 of August of 2026]. Available at: https://hdl.handle.net/2445/201724